Skip to main content

Enasidenib Pregnancy and Breastfeeding Warnings

Brand names: Idhifa

Medically reviewed by Last updated on May 24, 2023.

Enasidenib Pregnancy Warnings

Animal studies have revealed evidence of embryofetal mortality and growth alterations (e.g., spontaneous abortions, post-implantation loss, resorptions, decreased viable fetuses, lower fetal birth weights, skeletal variations) at maternally toxic doses starting at approximately 0.1 times the steady state clinical exposure based on the AUC at the recommended human dose. Changes in the reproductive organs of male and female animals (e.g., seminiferous tubular degeneration, hypospermia, atrophy of the seminal vesicle and prostate, decreased corpora lutea, increased atretic follicles in the ovaries, atrophy in the uterus) suggest this drug may impair fertility in females and males of reproductive potential; it is unknown whether these effects are reversible. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

Safety has not been established during pregnancy; based on animal studies, this drug can cause fetal harm.

US FDA pregnancy category: Not Assigned

-Obtain a pregnancy test on females of reproductive potential prior to treatment initiation.
-Direct females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment and for at least 1 month after the last dose.
-This drug may increase or decrease the concentrations of combined hormonal contraceptives; the clinical significance of this potential drug interaction is unknown.

See references

Enasidenib Breastfeeding Warnings

Breastfeeding is not recommended during treatment and for at least 1 month after the last dose.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant and on milk production are unknown.

See references

References for pregnancy information

  1. Product Information. Idhifa (enasidenib). Celgene Corporation. 2017.

References for breastfeeding information

  1. Product Information. Idhifa (enasidenib). Celgene Corporation. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.